PE20021083A1 - Moduladores de los receptores estrogenos - Google Patents
Moduladores de los receptores estrogenosInfo
- Publication number
- PE20021083A1 PE20021083A1 PE2002000308A PE2002000308A PE20021083A1 PE 20021083 A1 PE20021083 A1 PE 20021083A1 PE 2002000308 A PE2002000308 A PE 2002000308A PE 2002000308 A PE2002000308 A PE 2002000308A PE 20021083 A1 PE20021083 A1 PE 20021083A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- alkenyl
- modulators
- acetophenone
- Prior art date
Links
- 102000015694 estrogen receptors Human genes 0.000 title abstract 2
- 108010038795 estrogen receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 229940073735 4-hydroxy acetophenone Drugs 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003457 sulfones Chemical class 0.000 abstract 1
- 150000003462 sulfoxides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/08—Six-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA I DONDE R1 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, OR6, ENTRE OTROS; R2 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, ENTRE OTROS; R3 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, ENTRE OTROS; R4 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, ENTRE OTROS; R5 ES ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ENTRE OTROS; X E Y SON O, S, SULFOXIDO, SULFONA; R6 ES H, ALQUILO C1-C5, BENCILO, METOXIMETILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-TIOFENO-4-METOXI-ACETOFENONA, 2-TIOFENO-4-HIDROXI-ACETOFENONA, 2-TIOFENO-4-METOXI-ACETOFENONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON MODULADORES DE LOS RECEPTORES ESTROGENOS Y SON UTILES PARA EL TRATAMIENTO DE OSTEOPOROSIS, DEGENERACION DE CARTILAGO, ENDOMETRIOSIS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24158200P | 2000-10-19 | 2000-10-19 | |
| PCT/US2001/042735 WO2002032377A2 (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021083A1 true PE20021083A1 (es) | 2002-12-16 |
Family
ID=22911282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000308A PE20021083A1 (es) | 2000-10-19 | 2002-04-15 | Moduladores de los receptores estrogenos |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1333827A2 (es) |
| JP (1) | JP2004511502A (es) |
| KR (1) | KR20030042020A (es) |
| CN (1) | CN1469743A (es) |
| AU (2) | AU2002232381B2 (es) |
| BG (1) | BG107676A (es) |
| BR (1) | BR0114689A (es) |
| CA (1) | CA2424729A1 (es) |
| EA (1) | EA200300474A1 (es) |
| EC (1) | ECSP034558A (es) |
| EE (1) | EE200300153A (es) |
| HU (1) | HUP0303563A2 (es) |
| IL (1) | IL154984A0 (es) |
| IS (1) | IS6761A (es) |
| MX (1) | MXPA03003485A (es) |
| NO (1) | NO20031737L (es) |
| PE (1) | PE20021083A1 (es) |
| PL (1) | PL361053A1 (es) |
| SK (1) | SK4772003A3 (es) |
| WO (1) | WO2002032377A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225132A1 (en) * | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
| JP4554219B2 (ja) | 2002-04-24 | 2010-09-29 | メルク・シャープ・エンド・ドーム・コーポレイション | エストロゲン受容体調節剤 |
| NZ535705A (en) | 2002-05-10 | 2007-08-31 | Hoffmann La Roche | Ibandronic acid for the treatment and prevention of osteoporosis |
| EP1577288B1 (en) * | 2002-12-26 | 2014-07-23 | Eisai R&D Management Co., Ltd. | Selective estrogen receptor modulators |
| CN101365446B (zh) | 2005-07-29 | 2013-05-22 | 雷斯弗洛吉克斯公司 | 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送 |
| AU2006307046A1 (en) * | 2005-10-27 | 2007-05-03 | Msd K.K. | Novel benzoxathiin derivative |
| PL2118074T3 (pl) | 2007-02-01 | 2014-06-30 | Resverlogix Corp | Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego |
| JP5635535B2 (ja) | 2009-01-08 | 2014-12-03 | レスバーロジックス コーポレイション | 心血管疾患の予防および治療のための化合物 |
| WO2010106436A2 (en) | 2009-03-18 | 2010-09-23 | Resverlogix Corp. | Novel anti-inflammatory agents |
| TR201818390T4 (tr) | 2009-04-22 | 2019-01-21 | Resverlogix Corp | Yeni̇ anti̇-i̇nflamatuvar ajanlar |
| DK2580210T5 (en) | 2010-06-10 | 2017-06-19 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| TR201909777T4 (tr) | 2011-11-01 | 2019-07-22 | Resverlogix Corp | Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar |
| WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
-
2001
- 2001-10-15 BR BR0114689-0A patent/BR0114689A/pt not_active Application Discontinuation
- 2001-10-15 JP JP2002535616A patent/JP2004511502A/ja not_active Withdrawn
- 2001-10-15 MX MXPA03003485A patent/MXPA03003485A/es unknown
- 2001-10-15 KR KR10-2003-7005518A patent/KR20030042020A/ko not_active Withdrawn
- 2001-10-15 EP EP01987654A patent/EP1333827A2/en not_active Withdrawn
- 2001-10-15 IL IL15498401A patent/IL154984A0/xx unknown
- 2001-10-15 SK SK477-2003A patent/SK4772003A3/sk unknown
- 2001-10-15 EA EA200300474A patent/EA200300474A1/ru unknown
- 2001-10-15 HU HU0303563A patent/HUP0303563A2/hu unknown
- 2001-10-15 CN CNA018176720A patent/CN1469743A/zh active Pending
- 2001-10-15 EE EEP200300153A patent/EE200300153A/xx unknown
- 2001-10-15 WO PCT/US2001/042735 patent/WO2002032377A2/en not_active Ceased
- 2001-10-15 PL PL01361053A patent/PL361053A1/xx not_active Application Discontinuation
- 2001-10-15 AU AU2002232381A patent/AU2002232381B2/en not_active Ceased
- 2001-10-15 AU AU3238102A patent/AU3238102A/xx active Pending
- 2001-10-15 CA CA002424729A patent/CA2424729A1/en not_active Abandoned
-
2002
- 2002-04-15 PE PE2002000308A patent/PE20021083A1/es not_active Application Discontinuation
-
2003
- 2003-03-26 BG BG107676A patent/BG107676A/bg unknown
- 2003-03-27 IS IS6761A patent/IS6761A/is unknown
- 2003-04-15 NO NO20031737A patent/NO20031737L/no unknown
- 2003-04-17 EC EC2003004558A patent/ECSP034558A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002032377A3 (en) | 2002-08-22 |
| HUP0303563A2 (hu) | 2004-03-01 |
| WO2002032377A2 (en) | 2002-04-25 |
| AU2002232381B2 (en) | 2004-11-18 |
| MXPA03003485A (es) | 2003-07-14 |
| CN1469743A (zh) | 2004-01-21 |
| ECSP034558A (es) | 2003-06-25 |
| BR0114689A (pt) | 2003-07-01 |
| BG107676A (bg) | 2003-11-28 |
| JP2004511502A (ja) | 2004-04-15 |
| SK4772003A3 (en) | 2003-08-05 |
| IS6761A (is) | 2003-03-27 |
| AU3238102A (en) | 2002-04-29 |
| PL361053A1 (en) | 2004-09-20 |
| EE200300153A (et) | 2003-06-16 |
| EP1333827A2 (en) | 2003-08-13 |
| KR20030042020A (ko) | 2003-05-27 |
| CA2424729A1 (en) | 2002-04-25 |
| NO20031737L (no) | 2003-06-19 |
| EA200300474A1 (ru) | 2003-10-30 |
| NO20031737D0 (no) | 2003-04-15 |
| IL154984A0 (en) | 2003-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20021083A1 (es) | Moduladores de los receptores estrogenos | |
| PE20060401A1 (es) | Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno | |
| CY1109655T1 (el) | Συνδεση των παραγωγων κινουκλιδινης στους μουσκαρινικους υποδοχεις μ3 | |
| CR8753A (es) | Derivados de tetraazabenzo [e] azuleno y sus analogos | |
| CY1106486T1 (el) | Μεθοδος παρασκευης 2-(κινοξαλιν-5-υλσουλφονυλαμινο) βενζαμιδικων ενωσεων | |
| PE69299A1 (es) | Compuestos calciliticos | |
| ES2180981T3 (es) | Procedimiento para la preparacion de una sal de magnesio de un heterociclo de sulfinilo sustituido. | |
| PE20061084A1 (es) | Compuestos derivados de 2-ciano-3-(halo)alcoxi-bencenosulfonamida | |
| NO20041504L (no) | Lactamderivater som antagonister for humane 11CBY reseptorer. | |
| EA200970326A1 (ru) | Алкильные производные в качестве метаботропных рецепторов глутамата | |
| ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| ECSP034744A (es) | Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos | |
| DK1408961T3 (da) | 2 pyrrolidon-derivater som prostanoide agonister | |
| PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
| AR057981A1 (es) | Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion | |
| PA8576001A1 (es) | "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso". | |
| PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| ATE303369T1 (de) | Glucocorticoid rezeptor modulatoren | |
| PE20040678A1 (es) | Moduladores de los receptores selectivos de estrogenos | |
| PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| ATE327974T1 (de) | Modulatoren des glucocorticoid-rezeptors | |
| PE20060610A1 (es) | Derivados tetraciclicos como moduladores de los receptores de estrogeno | |
| PE20060590A1 (es) | COMPUESTOS ESTEROIDALES 15ß-SUSTITUIDOS CON ACTIVIDAD SELECTIVA DEL RECEPTOR DE ESTROGENOS | |
| EA200600694A1 (ru) | Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |